Hemoadsorption cartridge
Efferon® LPS
Restore Balance. Improve Outcomes. Reduce Costs.
Efferon® LPS is a third-generation extracorporeal blood purification device designed to complement standard sepsis care by targeting two key drivers of septic shock: endotoxins (lipopolysaccharides, LPS) and excess inflammatory mediators (cytokines).
Efferon® LPS is a non-pyrogenic, gamma-sterilized, single-use medical device.
- Sepsis of verified or suspected gram-negative aetiology, including septic shock.
- Critical endotoxemia: Elevated levels of endotoxin in the blood
- Cytokine storm syndrome: Elevated cytokines causing systemic inflammation
Dual Mechanism of Action
Unlike therapies that target only a single inflammatory pathway, Efferon® LPS simultaneously removes:
- Endotoxins (LPS) through a surface-immobilized selective ligand.
- Cytokines and inflammatory mediators through the intrinsic porosity of hypercrosslinked polystyrene beads.
By addressing both components of the dysregulated immune response, Efferon® LPS aims to help restore immune balance during septic shock.
Efferon® LPS – Key benefits
Based on the evidence from the LASSO multicenter randomized controlled trial1 (n=58 patients), treatment with Efferon® LPS can be associated with:
- Faster shock resolution: 2.3 days vs. 4.4 days (p=0.029)
- Higher shock recovery rate: 68% vs. 45% (p=0.098)
- Reduced vasopressor requirements: Significant reduction in median dosage at 48h and 72h (p<0.05)
- Faster mechanical ventilation weaning: 2.7 days vs. 4.7 days in survivors (p=0.038)
- Higher MV weaning success: 57% vs. 29% (p=0.037)
- Shorter ICU stay trend: 9 days vs. 14 days
- Shorter hospital stay trend: 15 days vs. 25 days
Efferon® NEO
Efferon® NEO is Europe's first multimodal hemoadsorption device CE MDR approved for neonatal and pediatric patients. It addresses a previously unmet need in critically ill children with sepsis.
Clinical Guidance
The role of hemoadsorption therapy is steadily expanding, particularly in acute care settings for the management of sepsis and severe systemic inflammation. However, despite its growing use and supporting evidence, there are still no internationally recognized clinical guidelines that clearly define when and how this therapy should be applied in daily clinical practice.
The Efferon® LPS Clinical Practice Guidance document has been developed by Efferon OÜ, the manufacturer of the Efferon® LPS device, to provide practical, evidence-based recommendations drawn from published studies, ongoing research, and real-world clinical experience. Its purpose is to support physicians in using Efferon® Therapy safely, effectively, and with confidence in their intensive care settings.
Conclusion
Efferon® LPS offers a comprehensive approach to blood purification in septic shock by combining dual-target removal of endotoxins and cytokines, evidence from a randomized controlled trial demonstrating improvements in clinically relevant outcomes, potential reductions in ICU resource utilization and hospital costs, and easy integration into existing extracorporeal therapy workflows.
Efferon® LPS & Efferon® NEO are available in most countries. To check registration and availability in your country or for any inquiries regarding Efferon® LPS & Efferon® NEO or Sepsis, don't hesitate to contact your local Aquarius representative or email sales@norrdia.com.
This document has been developed by Efferon OÜ, the manufacturer of the Efferon® LPS device, to provide practical, evidence-based recommendations drawn from published studies, ongoing research, and real-world clinical experience. Its purpose is to support physicians in using Efferon® Therapy safely, effectively, and with confidence in their intensive care settings.
